Cytokine Release Syndrome During Sequential Treatment With Immune Checkpoint Inhibitors and Kinase Inhibitors for Metastatic Melanoma

• Published in: Journal of immunotherapy (1997) Vol. 42; no. 1; p. 29
• Main Authors: Dimitriou, Florentia, Matter, Alexandra V, Mangana, Joanna, Urosevic-Maiwald, Mirjana, Micaletto, Sara, Braun, Ralph P, French, Lars E, Dummer, Reinhard
• Format: Journal Article
• Language: English
• Published: United States 01.01.2019
• Subjects: Antineoplastic Agents, Immunological - adverse effects; Antineoplastic Agents, Immunological - therapeutic use; Biomarkers; Biopsy; Cytokine Release Syndrome - diagnosis; Cytokine Release Syndrome - etiology; Female; Humans; Melanoma - complications; Melanoma - drug therapy; Melanoma - etiology; Melanoma - pathology; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Protein Kinase Inhibitors - adverse effects; Protein Kinase Inhibitors - therapeutic use; Proto-Oncogene Proteins B-raf - genetics

Switching from immunotherapy to targeted therapy in metastasized melanoma can be complicated by a cytokine release syndrome (CRS). CRS is a serious complication, which is induced by high levels of circulating cytokines, associated with T-cell engagement and proliferation, and results in a constellat...